In fall 2026, the Advarra-facilitated Site-Sponsor Consortium will release a white paper on reducing redundant site training through competency-based, role-based, and reusable training models while aligning with international regulatory guidelines.
This is Part 2 of a three-part series on the site initiation visit (SIV) aspect of training: where redundancy appears, what should remain live and study-specific, and how a better model could separate common training from protocol-specific readiness.
The SIV should be reserved for study-specific risk
Part 1 of this series focused on the data: SIV redundancy is predictable. The same categories keep appearing across training decks, including Good Clinical Practice (GCP) and regulatory readiness, safety reporting, monitoring and documentation expectations, and vendor platform training.
The next question is not whether SIVs should exist. They should. SIVs can provide invaluable information to site study teams. The real question is what belongs in the SIV and what should be moved elsewhere.
A useful principle is this: Live SIV time should be protected for content that varies materially by study, creates meaningful operational risk, or requires discussion between the sponsor, contract research organization (CRO), and site team.
The SIV should focus on what’s different
Many of the most important SIV topics aren’t generic. They’re highly specific to the protocol, disease area, investigational product, patient population, endpoint strategy, or operational model.
These are exactly the topics that can be diluted when training is crowded with generic GCP slides, copied regulatory text, vendor screenshots, and broad documentation reminders.
1. Protocol design and eligibility
Protocol design, inclusion and exclusion criteria, endpoints, visit schedules, assessment windows, and disease-specific background should remain central to the SIV.
Eligibility is one of the most consequential areas of study conduct. It’s also one of the areas where nuance matters most. Sites need to understand not only what the criteria say, but how the sponsor interprets them, where screen failures are likely, and which eligibility questions should be escalated before enrollment decisions are made.
2. Investigational product and dosing
Investigational product (IP) details also belong in the SIV when they affect conduct, safety, or compliance. This includes drug preparation, dose administration, titration, storage, shipment, accountability, device-specific handling, fasting requirements, prohibited medications, drug interactions, and dose modification rules.
These details vary materially from study to study. They often cannot be replaced by a generic training module. What matters is not simply that the site understands investigational product accountability in general, but that the site understands the specific risks and requirements of the protocol.
3. Disease-specific outcome measures
Disease-specific outcome measures should also be prioritized. A trial may depend on assessments that are unfamiliar, time-sensitive, subjective, technically complex, or tied to endpoint integrity.
The live SIV is the right place to clarify how these measures will be performed, who is responsible, what certification is required, what source documentation is expected, and what errors could compromise data quality.
4. Unique lab, imaging, and procedural workflows
Unique lab, imaging, and procedural workflows are another major category of study-specific content. This may include tissue requirements, biopsy schedules, pharmacokinetic sampling, electrocardiogram (ECG) timing relative to dosing, central lab processing, imaging upload requirements, endpoint-specific scans, or sample shipment windows.
These workflows often involve multiple staff roles and handoffs. A missed time point, improperly handled sample, rejected image, or incomplete requisition can create rework, missing data, protocol deviations, or patient burden. Live discussion is appropriate because the site needs to understand not only the steps, but the operational risk behind them.
5. Sponsor-specific safety and cohort rules
Sponsor-specific safety requirements belong in the SIV when they go beyond general adverse event (AE) and serious adverse event (SAE) reporting principles. This includes adverse events of special interest, unique reporting windows, dose-escalation rules, safety review committee processes, cohort governance, stopping rules, special monitoring requirements, and escalation pathways.
The generic concepts can be trained once. The protocol-specific thresholds and escalation rules should be discussed live.
Why this matters for oncology and other complex trials
The oncology-focused review showed many of the same redundant categories seen in the multi-therapeutic review, but it also highlighted why complex trials need sharper SIVs.
Oncology trials often involve layered eligibility criteria, disease-specific assessment schedules, tissue and biopsy requirements, central lab workflows, imaging workflows, pharmacokinetic sampling, dose modifications, prohibited medications, cohort rules, safety review committees, dose-escalation governance, and protocol-specific adverse events of special interest.
That does not mean oncology SIVs should be longer by default. It means the opposite: Non-study-specific content should move out of the way so oncology-specific content can receive the attention it deserves.
Complex studies do not need more generic training. They need more focused live discussion of study-specific operational risk.
A simple test for SIV content
Before including content in an SIV, sponsors and CROs could ask four questions:
- Does this topic vary materially by protocol, sponsor, investigational product, disease area, or endpoint?
- Would misunderstanding this topic create a meaningful risk to patient safety, data integrity, endpoint validity, enrollment quality, or study timelines?
- Does this topic require discussion, role clarification, scenario review, or site-specific planning?
- Is this topic something that cannot be trained effectively through a reusable module, job aid, or vendor-specific training?
If the answer to any of these is yes, the content may belong in the SIV.
If the answer to any of these is no, it doesn’t belong in the SIV.
Protecting the SIV
The purpose of reducing redundant SIV content isn’t to make training shorter for its own sake. The purpose is to protect attention.
Live SIV time is a limited resource. It should be used for the discussions only the study team and the site can have together: where the protocol is nuanced, where the risks are highest, where roles must be clarified, and where mistakes would matter.
Part 3 of this series will turn from content selection to training design: a better direction that separates reusable core training, vendor micro-training, and live protocol-specific discussion without giving up study-specific quality.
